Which has better valuation & earnings, ABBV or INCY?

AbbVie has higher revenue and earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AbbVie $61.16B 7.24 $4.23B $3.54 70.77 Incyte $5.14B 4.87 $1.29B $7.85 15.73

Is ABBV or INCY more profitable?

Incyte has a net margin of 27.71% compared to AbbVie's net margin of 9.80%. Incyte's return on equity of 29.93% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets AbbVie 9.80% -422.07% 14.34% Incyte 27.71% 29.93% 22.88%

Does the media prefer ABBV or INCY?

In the previous week, AbbVie had 46 more articles in the media than Incyte. MarketBeat recorded 55 mentions for AbbVie and 9 mentions for Incyte. Incyte's average media sentiment score of 1.60 beat AbbVie's score of 1.18 indicating that Incyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbbVie 37 Very Positive mention(s) 9 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Incyte 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor INCY or REGN?

In the previous week, Regeneron Pharmaceuticals had 34 more articles in the media than Incyte. MarketBeat recorded 43 mentions for Regeneron Pharmaceuticals and 9 mentions for Incyte. Incyte's average media sentiment score of 1.60 beat Regeneron Pharmaceuticals' score of 0.58 indicating that Incyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Regeneron Pharmaceuticals 17 Very Positive mention(s) 2 Positive mention(s) 19 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has stronger valuation & earnings, ARGX or INCY?

argenex has higher earnings, but lower revenue than Incyte. Incyte is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio argenex $4.25B 14.55 $1.29B $26.04 37.94 Incyte $5.14B 4.87 $1.29B $7.85 15.73

Is ARGX or INCY more profitable?

argenex has a net margin of 32.19% compared to Incyte's net margin of 27.71%. argenex's return on equity of 43.59% beat Incyte's return on equity. Company Net Margins Return on Equity Return on Assets argenex 32.19% 43.59% 36.66% Incyte 27.71% 29.93% 22.88%

Does the media prefer ARGX or INCY?

In the previous week, argenex had 11 more articles in the media than Incyte. MarketBeat recorded 20 mentions for argenex and 9 mentions for Incyte. Incyte's average media sentiment score of 1.60 beat argenex's score of 0.82 indicating that Incyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 7 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Incyte 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger earnings and valuation, INCY or NTRA?

Incyte has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Incyte $5.14B 4.87 $1.29B $7.85 15.73 Natera $2.31B 19.64 -$208.16M -$1.36 N/A

Is INCY or NTRA more profitable?

Incyte has a net margin of 27.71% compared to Natera's net margin of -7.11%. Incyte's return on equity of 29.93% beat Natera's return on equity. Company Net Margins Return on Equity Return on Assets Incyte 27.71% 29.93% 22.88% Natera -7.11% -11.38% -7.87%

Does the media prefer INCY or NTRA?

In the previous week, Natera had 16 more articles in the media than Incyte. MarketBeat recorded 25 mentions for Natera and 9 mentions for Incyte. Incyte's average media sentiment score of 1.60 beat Natera's score of 0.94 indicating that Incyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Natera 11 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RVMD or INCY?

In the previous week, Revolution Medicines had 4 more articles in the media than Incyte. MarketBeat recorded 13 mentions for Revolution Medicines and 9 mentions for Incyte. Incyte's average media sentiment score of 1.60 beat Revolution Medicines' score of 1.06 indicating that Incyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 8 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Incyte 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Incyte (INCY) Competitors

$123.50 +3.34 (+2.78%)

As of 08/17/2026 04:00 PM Eastern

Compare

INCY vs. ABBV, REGN, ARGX, NTRA, and RVMD

Should you buy Incyte stock or one of its competitors? Incyte's main competitors and comparable companies include AbbVie (ABBV), Regeneron Pharmaceuticals (REGN), argenex (ARGX), Natera (NTRA), and Revolution Medicines (RVMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Incyte compare to AbbVie?

AbbVie (NYSE:ABBV) and Incyte (NASDAQ:INCY) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

AbbVie has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market. Comparatively, Incyte has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market.

AbbVie has higher revenue and earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbbVie	$61.16B	7.24	$4.23B	$3.54	70.77
Incyte	$5.14B	4.87	$1.29B	$7.85	15.73

In the previous week, AbbVie had 46 more articles in the media than Incyte. MarketBeat recorded 55 mentions for AbbVie and 9 mentions for Incyte. Incyte's average media sentiment score of 1.60 beat AbbVie's score of 1.18 indicating that Incyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbbVie	37 Very Positive mention(s)	9 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Incyte	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

AbbVie currently has a consensus target price of $275.73, suggesting a potential upside of 10.06%. Incyte has a consensus target price of $121.65, suggesting a potential downside of 1.50%. Given AbbVie's stronger consensus rating and higher probable upside, equities research analysts plainly believe AbbVie is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbbVie	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.88
Incyte	0 Sell rating(s)	13 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.43

Incyte has a net margin of 27.71% compared to AbbVie's net margin of 9.80%. Incyte's return on equity of 29.93% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbbVie	9.80%	-422.07%	14.34%
Incyte	27.71%	29.93%	22.88%

70.2% of AbbVie shares are held by institutional investors. Comparatively, 97.0% of Incyte shares are held by institutional investors. 0.1% of AbbVie shares are held by company insiders. Comparatively, 16.2% of Incyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

AbbVie beats Incyte on 9 of the 17 factors compared between the two stocks.

How does Incyte compare to Regeneron Pharmaceuticals?

Incyte (NASDAQ:INCY) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

Incyte has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.21, meaning that its share price is 79% less volatile than the broader market.

In the previous week, Regeneron Pharmaceuticals had 34 more articles in the media than Incyte. MarketBeat recorded 43 mentions for Regeneron Pharmaceuticals and 9 mentions for Incyte. Incyte's average media sentiment score of 1.60 beat Regeneron Pharmaceuticals' score of 0.58 indicating that Incyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Regeneron Pharmaceuticals	17 Very Positive mention(s)	2 Positive mention(s)	19 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Incyte presently has a consensus target price of $121.65, indicating a potential downside of 1.50%. Regeneron Pharmaceuticals has a consensus target price of $801.70, indicating a potential downside of 0.53%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	0 Sell rating(s)	13 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.43
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.62

Regeneron Pharmaceuticals has higher revenue and earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	4.87	$1.29B	$7.85	15.73
Regeneron Pharmaceuticals	$14.34B	5.79	$4.50B	$40.46	19.92

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Incyte's net margin of 27.71%. Incyte's return on equity of 29.93% beat Regeneron Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	27.71%	29.93%	22.88%
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%

97.0% of Incyte shares are owned by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 16.2% of Incyte shares are owned by company insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Regeneron Pharmaceuticals beats Incyte on 10 of the 16 factors compared between the two stocks.

How does Incyte compare to argenex?

argenex (NASDAQ:ARGX) and Incyte (NASDAQ:INCY) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

argenex has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market. Comparatively, Incyte has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market.

argenex has higher earnings, but lower revenue than Incyte. Incyte is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	14.55	$1.29B	$26.04	37.94
Incyte	$5.14B	4.87	$1.29B	$7.85	15.73

In the previous week, argenex had 11 more articles in the media than Incyte. MarketBeat recorded 20 mentions for argenex and 9 mentions for Incyte. Incyte's average media sentiment score of 1.60 beat argenex's score of 0.82 indicating that Incyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	7 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Incyte	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

argenex currently has a consensus target price of $1,072.72, suggesting a potential upside of 8.59%. Incyte has a consensus target price of $121.65, suggesting a potential downside of 1.50%. Given argenex's stronger consensus rating and higher probable upside, research analysts clearly believe argenex is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92
Incyte	0 Sell rating(s)	13 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.43

60.3% of argenex shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 2.4% of argenex shares are owned by insiders. Comparatively, 16.2% of Incyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

argenex has a net margin of 32.19% compared to Incyte's net margin of 27.71%. argenex's return on equity of 43.59% beat Incyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	32.19%	43.59%	36.66%
Incyte	27.71%	29.93%	22.88%

Summary

argenex beats Incyte on 12 of the 17 factors compared between the two stocks.

How does Incyte compare to Natera?

Incyte (NASDAQ:INCY) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.

Incyte presently has a consensus target price of $121.65, suggesting a potential downside of 1.50%. Natera has a consensus target price of $319.38, suggesting a potential upside of 1.65%. Given Natera's stronger consensus rating and higher possible upside, analysts clearly believe Natera is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	0 Sell rating(s)	13 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.43
Natera	1 Sell rating(s)	4 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.82

Incyte has a net margin of 27.71% compared to Natera's net margin of -7.11%. Incyte's return on equity of 29.93% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	27.71%	29.93%	22.88%
Natera	-7.11%	-11.38%	-7.87%

In the previous week, Natera had 16 more articles in the media than Incyte. MarketBeat recorded 25 mentions for Natera and 9 mentions for Incyte. Incyte's average media sentiment score of 1.60 beat Natera's score of 0.94 indicating that Incyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Natera	11 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Incyte has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	4.87	$1.29B	$7.85	15.73
Natera	$2.31B	19.64	-$208.16M	-$1.36	N/A

97.0% of Incyte shares are held by institutional investors. Comparatively, 99.9% of Natera shares are held by institutional investors. 16.2% of Incyte shares are held by company insiders. Comparatively, 5.1% of Natera shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Incyte has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, Natera has a beta of 1.51, indicating that its stock price is 51% more volatile than the broader market.

Summary

Incyte beats Natera on 9 of the 17 factors compared between the two stocks.

How does Incyte compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Incyte (NASDAQ:INCY) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.

Incyte has a net margin of 27.71% compared to Revolution Medicines' net margin of 0.00%. Incyte's return on equity of 29.93% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-88.20%	-57.85%
Incyte	27.71%	29.93%	22.88%

Revolution Medicines has a beta of 1.39, indicating that its share price is 39% more volatile than the broader market. Comparatively, Incyte has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market.

Revolution Medicines currently has a consensus target price of $166.33, indicating a potential downside of 21.54%. Incyte has a consensus target price of $121.65, indicating a potential downside of 1.50%. Given Incyte's higher probable upside, analysts clearly believe Incyte is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90
Incyte	0 Sell rating(s)	13 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.43

94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 97.0% of Incyte shares are held by institutional investors. 7.6% of Revolution Medicines shares are held by insiders. Comparatively, 16.2% of Incyte shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Incyte has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	3,924.01	-$1.13B	-$8.82	N/A
Incyte	$5.14B	4.87	$1.29B	$7.85	15.73

In the previous week, Revolution Medicines had 4 more articles in the media than Incyte. MarketBeat recorded 13 mentions for Revolution Medicines and 9 mentions for Incyte. Incyte's average media sentiment score of 1.60 beat Revolution Medicines' score of 1.06 indicating that Incyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	8 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Incyte	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Incyte beats Revolution Medicines on 11 of the 17 factors compared between the two stocks.

Get Incyte News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INCY vs. The Competition

Export

Metric	Incyte	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$24.36B	$3.74B	$7.03B	$13.06B
Dividend Yield	N/A	3.69%	2.56%	10.62%
P/E Ratio	15.73	11.49	270.86	25.39
Price / Sales	4.87	1,307.41	605.48	91.31
Price / Cash	19.44	45.11	28.87	38.47
Price / Book	4.69	17.17	11.09	6.51
Net Income	$1.29B	-$13.18M	$3.45B	$347.22M
7 Day Performance	2.01%	0.88%	0.62%	1.27%
1 Month Performance	5.33%	2.59%	2.09%	2.72%
1 Year Performance	45.43%	53.95%	61.59%	21.85%

Incyte Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INCY Incyte	3.6134 of 5 stars	$123.50 +2.8%	$121.65 -1.5%	+42.1%	$24.36B	$5.14B	15.73	2,844	Positive News Analyst Forecast
ABBV AbbVie	4.8854 of 5 stars	$247.86 +0.7%	$275.70 +11.2%	+21.2%	$434.70B	$61.16B	70.02	57,000	Positive News Analyst Forecast
REGN Regeneron Pharmaceuticals	3.7651 of 5 stars	$808.05 +3.0%	$797.75 -1.3%	+38.9%	$80.75B	$14.34B	19.97	15,410	Analyst Upgrade
ARGX argenex	4.359 of 5 stars	$866.11 +0.1%	$1,056.89 +22.0%	+51.1%	$54.12B	$4.25B	33.26	1,863	Analyst Downgrade
NTRA Natera	2.7667 of 5 stars	$318.35 -1.2%	$301.90 -5.2%	+92.7%	$46.13B	$2.31B	N/A	6,140

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INCY) was last updated on 8/18/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Incyte (INCY) Competitors